real-world-benefit-shown-in-T2D-treatment
Empagliflozin reduced the risk of cardiovascular events and hospitalization for heart failure compared to DPP-4 inhibitors in people with type 2 diabetes Interim analysis of the EMPRISE real-world evidence study showed that empagliflozin was associated with a reduced risk in all-cause mortality, hospitalization for heart failure and acute kidney injury requiring dialysis, compared to DPP-4 inhibitorsThis analysis, which includes European data pooled with data from Israel and East Asia, was presented for the first time at the American Diabetes Association Scientific Sessions, 25 June 20211 EMPRISE data complement the landmark EMPA-REG OUTCOME ® trial
Source: Boehringer Ingelheim Corporate News - Category: Research Source Type: news
More News: Cardiology | Cardiovascular | Diabetes | Diabetes Type 2 | Dialysis | Empagliflozin | Endocrinology | Heart | Heart Failure | Israel Health | Jardiance | Middle East Health | Research | Study | Urology & Nephrology